Roivant Sciences (ROIV) Price & Analysis

Compare

666 Followers

ROIV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.73 - $14.48

Previous CloseN/A

Volume1.46M

Average Volume (3M)6.28M

Market Cap

$9.53B

Enterprise Value$3.73B

Total Cash (Recent Filing)$4.50B

Total Debt (Recent Filing)$99.69M

Price to Earnings (P/E)1.9

Beta0.99

Next Earnings

Nov 17, 2025

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding682,881,700

10 Day Avg. Volume9,482,756

30 Day Avg. Volume6,280,118

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.39

Enterprise Value/Revenue160.61

Enterprise Value/Gross Profit177.70

Enterprise Value/Ebitda-3.80

Forecast

1Y Price Target

$19.81

Price Target Upside29.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Product LaunchThe attractiveness of once-daily oral dosing and favorable tolerability are strong reasons for optimism about the drug's launch.

Regulatory ApprovalManagement plans to file for FDA approval, and including steroid tapering on the label will be discussed, which is important for physicians and patients.

Bears Say

Market CompetitionThere is increasing competition in Graves' disease and thyroid eye disease, with novel therapies being developed by other companies.

Regulatory RisksThere are clinical and regulatory risks common to biotech companies at this stage in development, which could impact Roivant's rating and price target.

Roivant Sciences News

Roivant Sciences price target raised to $16.50 from $12 at BofA

BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $16.50 from $12 and...

9h ago

ROIV

TD Cowen initiates $23 price target for Roivant Sciences

TD Cowen initiated a $24 price target for Roivant Sciences (ROIV) following the release of its announcement that...

9h ago

ROIV

Roivant Sciences price target raised to $20 from $18 at Jefferies

Jefferies raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $18 and keeps a Buy...

9h ago

MRNA

ROIV

Roivant Sciences price target raised to $21 from $15 at Guggenheim

Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $21 from $15 and keeps a Buy...

9h ago

ROIV

Roivant Sciences price target raised to $20 from $16 at JPMorgan

JPMorgan raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $16 and keeps an Overweight...

10h ago

ROIV

Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $18 and keeps a...

11h ago

ROIV

Roivant Sciences rises 11.2%

Roivant Sciences (ROIV) is up 11.2%, or $1.59 to $15.77. Published first on TheFly – the ultimate source...

1d ago

ROIV

General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz

The major averages were mixed near noon ahead of the Federal Reserve’s meeting later in the day. The...

1d ago

Roivant Sciences rises 12.0%

Roivant Sciences (ROIV) is up 12.0%, or $1.70 to $15.88. Published first on TheFly – the ultimate source...

1d ago

ROIV

Roivant, Priovant reports Phase 3 VALOR study results for brepocitinib

Roivant and Priovant Therapeutics announced results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis. On the...

1d ago

ROIV

3 Stocks to Buy Now, According to the Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

28d ago

CXW

ACLX

Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis

TD Cowen analyst Yaron Werber has maintained their bullish stance on ROIV stock, giving a Buy rating today....

23h ago

ROIV

Roivant Sciences Announces Positive Phase 3 Study Results

Roivant Sciences ( ($ROIV) ) has provided an update. On September 17, 2025, Roivant Sciences announced positive results...

1d ago

ROIV

Roivant Sciences Approves Proposals at Annual Meeting

An update from Roivant Sciences ( ($ROIV) ) is now available. On September 10, 2025, Roivant Sciences Ltd....

7d ago

ROIV

ROIV FAQ

What was Roivant Sciences’s price range in the past 12 months?

Roivant Sciences lowest stock price was $8.73 and its highest was $14.47 in the past 12 months.

What is Roivant Sciences’s market cap?

Roivant Sciences’s market cap is $9.53B.

When is Roivant Sciences’s upcoming earnings report date?

Roivant Sciences’s upcoming earnings report date is Nov 17, 2025 which is in 60 days.

How were Roivant Sciences’s earnings last quarter?

Roivant Sciences released its earnings results on Aug 11, 2025. The company reported -$0.252 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.002.

Is Roivant Sciences overvalued?

According to Wall Street analysts Roivant Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences pay dividends?

Roivant Sciences does not currently pay dividends.

What is Roivant Sciences’s EPS estimate?

Roivant Sciences’s EPS estimate is -0.32.

How many shares outstanding does Roivant Sciences have?

Roivant Sciences has 682,881,700 shares outstanding.

What happened to Roivant Sciences’s price movement after its last earnings report?

Roivant Sciences reported an EPS of -$0.252 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -2.785%.

Which hedge fund is a major shareholder of Roivant Sciences?

Currently, no hedge funds are holding shares in ROIV

Roivant Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.84%

Trailing 12-Months

Asset Growth

-22.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Roivant Sciences

Roivant Sciences (ROIV) is a biopharmaceutical company focused on developing transformative medicines by building 'Vants,' which are nimble, entrepreneurial biotech companies. Each Vant operates with an independent management team and focuses on a specific therapeutic area or technology. Roivant's core products and services include drug development in areas such as neurology, immunology, and rare diseases, with an emphasis on innovation and rapid commercialization.

Roivant Sciences (ROIV) Earnings & Revenues

Historic Earnings Reports

ROIV Company Deck

ROIV Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.View all ROIV earnings summaries

ROIV Stock 12 Month Forecast

Average Price Target

$19.81

▲(29.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","12.25":"$12.25","16.5":"$16.5","20.75":"$20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12.25,16.5,20.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,13.283076923076923,14.176153846153847,15.069230769230769,15.962307692307693,16.855384615384615,17.748461538461537,18.64153846153846,19.534615384615385,20.427692307692308,21.32076923076923,22.213846153846156,23.106923076923074,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.96076923076923,13.531538461538462,14.102307692307692,14.673076923076923,15.243846153846153,15.814615384615383,16.385384615384616,16.956153846153846,17.526923076923076,18.097692307692306,18.668461538461536,19.239230769230765,{"y":19.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.667692307692308,12.945384615384615,13.223076923076924,13.500769230769231,13.778461538461539,14.056153846153846,14.333846153846153,14.611538461538462,14.88923076923077,15.166923076923077,15.444615384615386,15.722307692307691,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >